<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04995380</url>
  </required_header>
  <id_info>
    <org_study_id>20210057631</org_study_id>
    <nct_id>NCT04995380</nct_id>
  </id_info>
  <brief_title>Validation and Comparison of Scores for Prediction of RIsk for Post-operative Major Morbidity After Cholecystectomy in Acute Calculous Cholecystitis (SPRIMACC)</brief_title>
  <acronym>SPRIMACC</acronym>
  <official_title>Validation and Comparison of Scores for Prediction of RIsk for Post-operative Major Morbidity After Cholecystectomy in Acute Calculous Cholecystitis: Protocol for a Prospective Multicenter Observational Study (SPRIMACC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Policlinico S. Matteo</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SPRIMACC study is a prospective multicenter observational study with the primary endpoint&#xD;
      to prospectively validate the Chole-Risk score in predicting a complicated postoperative&#xD;
      course (post-operative major complications (Clavien-Dindo&gt;=3a), length of stay (LOS) &gt; 10&#xD;
      days or need of readmission within 30 days from the discharge) in patients undergoing Early&#xD;
      Cholecystectomy (EC) for Acute Calculous Cholecystitis (ACC). The secondary endpoints of the&#xD;
      study are to prospectively validate and compare other wellknown risk prediction models (the&#xD;
      POSSUM/P-POSSUM score, the Modified Frailty Index (mFI), the Charlson Comorbidity Index&#xD;
      (CCI), the American Society of Anesthesiologists (ASA) score and the APACHE II score) in&#xD;
      predicting a complicated post-operative course in patients undergoing EC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Complicated post-operative course</measure>
    <time_frame>30 days after discharge</time_frame>
    <description>The study outcome is a composite outcome including:&#xD;
30-day post-operative major morbidity, intended as Clavien-Dindo &gt;= 3a complication&#xD;
length of stay (LOS) &gt; 10 days&#xD;
readmission within 30 days from the discharge&#xD;
after Early Cholecystectomy for Acute Calculous Cholecystis. It is a binary outcome (0/1): in the event of a, b or c occurring, the patient's course is defined as complicated (1). If neither a, b, nor c occur, the course is defined as uncomplicated (0).</description>
  </primary_outcome>
  <enrollment type="Anticipated">663</enrollment>
  <condition>Acute Cholecystitis</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Early Cholecystectomy</intervention_name>
    <description>Cholecystectomy performed within 10 days from onset of symptoms</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patients presenting with ACC as defined according to the Tokyo Guidelines&#xD;
        2018 to one of the participating hospitals will be assessed for eligibility on&#xD;
        presentation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  have a diagnosis of Acute Calculous Cholecystitis (ACC) as defined by Tokyo Guidelines&#xD;
             2018 criteria&#xD;
&#xD;
          -  be candidate to Early Cholecystectomy (EC) during the index admission*&#xD;
&#xD;
          -  be ≥ 18 years old&#xD;
&#xD;
          -  be stratified for the risk of Common Bile Duct Stones (CBDS) according to the&#xD;
             Israelian Score, and, in case of confirmation of CBDS receive pre-operative Endoscopic&#xD;
             Retrograde Cholangiopancreatography (ERCP).&#xD;
&#xD;
          -  provide signed and dated informed consent form&#xD;
&#xD;
          -  willing to comply with all study procedures and be available for the duration of the&#xD;
             study.&#xD;
&#xD;
               -  All the patients treated with initial open cholecystectomy, those who undergo&#xD;
                  Early Laparoscopic Cholecystectomy (ELC), those with conversion from laparoscopic&#xD;
                  to open cholecystectomy or those who undergo bail out procedures (e.g. subtotal&#xD;
                  cholecystectomy) will be included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy or lactation&#xD;
&#xD;
          -  acute cholecystitis not related to a gallstone etiology&#xD;
&#xD;
          -  onset of symptoms &gt;10 days before cholecystectomy**&#xD;
&#xD;
          -  concomitant cholangitis or pancreatitis&#xD;
&#xD;
          -  intraoperative treatment of common bile duct stones&#xD;
&#xD;
          -  anything that would place the individual at increased risk or preclude the&#xD;
             individual's full compliance with or completion of the study.&#xD;
&#xD;
               -  Patients with ACC associated with common bile duct stones who underwent&#xD;
                  pre-operative ERCP could be included if they receive EC within 10 days from onset&#xD;
                  of symptoms&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paola Fugazzola</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Policlinico San Matteo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paola Fugazzola, MD</last_name>
    <phone>+390382252579</phone>
    <email>paola.fugazzola@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chirurgia 1, Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Fugazzola, MD</last_name>
      <phone>+390382252579</phone>
      <email>paola.fugazzola@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Paola Fugazzola</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorenzo Cobianchi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matteo Tomasoni</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mario Improta</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luca Ansaloni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of General and Digestive Surgery Hospital Universitario La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) Universidad Autónoma de Madrid (UAM),</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcello Di Martino</last_name>
      <email>marcellodima@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marcello Di Martino</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ángela de la Hoz Rodríguez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Martín- Pérez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Di Martino M, Mora-Guzmán I, Jodra VV, Dehesa AS, García DM, Ruiz RC, Nisa FG, Moreno FM, Batanero SA, Sampedro JEQ, Cumplido PL, Bravo AA, Rubio-Perez I, Asensio-Gomez L, Aranda FP, Farrarons SS, Moreno CR, Moreno CMM, Lasarte AS, Calvo MP, Aparicio-Sánchez D, Del Pozo EP, Pellino G, Martin-Perez E. How to Predict Postoperative Complications After Early Laparoscopic Cholecystectomy for Acute Cholecystitis: the Chole-Risk Score. J Gastrointest Surg. 2021 Feb 24. doi: 10.1007/s11605-021-04956-9. [Epub ahead of print]</citation>
    <PMID>33629230</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>October 31, 2021</last_update_submitted>
  <last_update_submitted_qc>October 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Matteo</investigator_affiliation>
    <investigator_full_name>Paola Fugazzola</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecystitis</mesh_term>
    <mesh_term>Acalculous Cholecystitis</mesh_term>
    <mesh_term>Cholecystitis, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

